Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris Inc. (NASDAQ: VTRS) will announce its financial results for Q3 2022 on November 7, 2022, at 8:30 a.m. ET. Key executives, including Executive Chairman Robert J. Coury and CEO Michael Goettler, will host a webcast reviewing the quarterly results and an update regarding the February 28 Investor Event. Investors can access the live call via investor.viatris.com or by calling provided numbers. Viatris, established in November 2020, focuses on providing global healthcare solutions through its extensive portfolio of approved products.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) will participate in the BofA Global Research Global Healthcare Conference on September 15, 2022, in London. The event will feature a fireside chat with CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula, scheduled for 4:45 p.m. BST / 11:45 a.m. ET. A live webcast will be available at investor.viatris.com, along with an archived version post-event. Viatris, formed in November 2020, aims to enhance global health by providing access to over 1,400 medicines.
Viatris reported total revenues of $4.12 billion with U.S. GAAP net earnings at $314 million and adjusted EBITDA of $1.48 billion. The company generated U.S. GAAP net cash provided by operating activities of $803 million and free cash flow of $719 million in the first half of 2022. Despite facing foreign exchange headwinds, it reaffirms guidance for adjusted EBITDA and free cash flow, while revising total revenues guidance to reflect currency impacts. A quarterly dividend of $0.12 per share was declared, and the company paid down $1.5 billion in debt with a target of $2 billion for the full year.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2022 financial results on August 8 before U.S. market opening. A live webcast will be held at 8:30 a.m. ET on the same day to discuss the results. Viatris, formed in November 2020, offers over 1,400 approved molecules across various therapeutic areas and operates globally with around 37,000 employees. The company's mission is to provide access to high-quality medicines, leveraging its extensive portfolio and global healthcare capabilities.
Viatris Inc. (NASDAQ: VTRS) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, in Rancho Palos Verdes, CA. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will engage in a fireside chat at 1:20 p.m. PT. A live webcast of the event will be available on investor.viatris.com and an archived version will follow.
Viatris, formed in November 2020, operates globally with a portfolio of over 1,400 approved molecules across diverse therapeutic areas.
Summary not available.
Viatris reported strong first-quarter 2022 results, achieving total revenues of $4.19 billion and U.S. GAAP net earnings of $399.2 million. Adjusted EBITDA stood at $1.59 billion, with free cash flow reaching $1.07 billion. The company confirmed its $600 million new product revenue target and made significant progress on its debt repayment strategy, paying down $840 million of debt. Additionally, a quarterly dividend of $0.12 per share was declared. The ongoing conflict in Ukraine has had limited immediate impact but poses potential future risks.
Viatris Inc. (NASDAQ: VTRS) will announce its Q1 2022 financial results on May 9, 2022, before U.S. market opening. The announcement will be followed by a live webcast at 8:30 a.m. EDT, featuring executives including CEO Michael Goettler and CFO Sanjeev Narula. The company aims to provide insights on its performance since being formed in November 2020, leveraging extensive expertise to deliver high-quality medicines globally.
On March 30, 2022, Viatris Inc. (NASDAQ: VTRS) partnered with Sesame Workshop to launch new bilingual resources to support the emotional and social needs of families impacted by the COVID-19 pandemic. This initiative includes five videos featuring popular characters like Elmo and Grover, aimed at helping children and caregivers navigate emotions and adapt to changes. The project is part of the Caring for Each Other initiative, reaching families in over 100 countries. Viatris's commitment to global health is highlighted as they continue to provide resources to ease anxieties stemming from the pandemic.